Drug Profile
BLNP 020
Alternative Names: BLNP-020Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator BL-&-H
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Subcutaneous fat disorders
- Discontinued Liver cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Subcutaneous fat disorders in South Korea
- 20 Feb 2019 Clinical trials in Subcutaneous fat disorders in South Korea (unspecified route) (BL & H pipeline, February 2019)
- 17 Oct 2018 Discontinued - Preregistration for Liver cancer in South Korea (unspecified route)